Beren Adrabetadex PDUFA Extended to Nov 17 for NPC

The FDA extended its review of Beren Therapeutics’ NDA for adrabetadex, an intrathecal cyclodextrin therapy for infantile-onset Niemann-Pick disease type C (I-NPC). The new PDUFA date is November 17, 2026, pushed back three months from the original August 17 target.

The extension follows Beren’s March 18, 2026 response to an FDA information request. The FDA classified that response as a Major Amendment, which under agency regulations automatically extends the review clock by three months. This is a procedural step, not a signal of safety or efficacy concerns. The company’s press release confirms the review is ongoing.

Beren Therapeutics is a private public benefit corporation, not a publicly traded company. There is no stock ticker to track. The company, through its subsidiary Mandos LLC, is developing adrabetadex as the only therapy designed to directly target the underlying pathophysiology of NPC.

Niemann-Pick disease type C is a rare, autosomal-recessive neurodegenerative disorder caused by pathogenic variants in the NPC1 or NPC2 genes. These mutations impair intracellular cholesterol trafficking, leading to progressive neurological decline and premature death. Mean age of death is approximately 5.6 years for early infantile onset and 13.4 years for late-infantile onset. There are no FDA-approved disease-modifying therapies for NPC.

Adrabetadex is a proprietary mixture of 2-hydroxypropyl-beta-cyclodextrin isomers delivered intrathecally, directly into the spinal canal. This route allows the cyclodextrin to reach the central nervous system, where it is intended to restore cholesterol trafficking in neural cells. The drug received Orphan Drug and Breakthrough Therapy designations.

The NPC competitive field is narrow. Zevra Therapeutics’ Miplyffa (arimoclomol) received a negative CHMP opinion in Europe earlier in 2026, though it was approved in the US in September 2024 for a broader NPC population. Miplyffa works through a different mechanism, amplifying heat shock proteins to improve lysosomal function. If adrabetadex is approved, it would be the first therapy to address the cholesterol trafficking defect directly.

Beren continues to provide access to adrabetadex through an Expanded Access Program during the extended review period. The NDA was granted Priority Review. Data presented at the 2026 ACMG Annual Meeting supported the filing.

The key risk for investors watching this space: Beren is private, so the November 17 decision will not move a stock directly. However, the outcome matters for the broader rare-disease ecosystem. An approval would validate intrathecal cyclodextrin delivery as a viable therapeutic approach for lysosomal storage disorders with CNS involvement, a concept that has been studied in preclinical work for decades without reaching the market.

Safety monitoring will be central. The most common adverse events observed with adrabetadex include hearing impairment, post-dose fatigue, and ataxia. Hearing loss has been a recognized concern in prior intrathecal cyclodextrin development, and baseline and longitudinal audiologic assessment will likely be required if the drug is approved.

What to watch: the November 17 decision. The extension is procedural, but the FDA will now have three additional months to review the Major Amendment data. Any further information requests from the agency before that date would signal that the review is not straightforward.